MX2009009917A - Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer. - Google Patents
Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer.Info
- Publication number
- MX2009009917A MX2009009917A MX2009009917A MX2009009917A MX2009009917A MX 2009009917 A MX2009009917 A MX 2009009917A MX 2009009917 A MX2009009917 A MX 2009009917A MX 2009009917 A MX2009009917 A MX 2009009917A MX 2009009917 A MX2009009917 A MX 2009009917A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- treating cancer
- tetrahydroquinoline derivatives
- tetrahydroquinoline
- derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la fórmula I (ver fórmula (I)) en donde E, R3, R4, R5, X, Y, W, Q1, Q2, Z, s y m tienen los significados indicados en la reivindicación 1, se pueden utilizar, entre otras cosas, para el tratamiento de tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007013854A DE102007013854A1 (de) | 2007-03-20 | 2007-03-20 | Tetrahydrochinoline |
PCT/EP2008/001422 WO2008113456A1 (de) | 2007-03-20 | 2008-02-22 | Tetrahydrochinolinederivate und ihre verwendung zur behandlung von krebs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009009917A true MX2009009917A (es) | 2009-10-19 |
Family
ID=39692561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009917A MX2009009917A (es) | 2007-03-20 | 2008-02-22 | Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100076012A1 (es) |
EP (1) | EP2121706A1 (es) |
JP (1) | JP2010521505A (es) |
KR (1) | KR20090130071A (es) |
CN (1) | CN101636401A (es) |
AR (1) | AR065786A1 (es) |
AU (1) | AU2008228570A1 (es) |
BR (1) | BRPI0808742A2 (es) |
CA (1) | CA2681261A1 (es) |
DE (1) | DE102007013854A1 (es) |
EA (1) | EA200901180A1 (es) |
IL (1) | IL200966A0 (es) |
MX (1) | MX2009009917A (es) |
WO (1) | WO2008113456A1 (es) |
ZA (1) | ZA200907306B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011084439A1 (en) * | 2009-12-17 | 2011-07-14 | Sanofi | Tetrahydrocarboline derivatives as eg5 inhibitors |
CN103328449A (zh) * | 2011-01-26 | 2013-09-25 | 霍夫曼-拉罗奇有限公司 | 新的四氢喹啉衍生物 |
US9745325B2 (en) * | 2014-04-18 | 2017-08-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
CA2975605C (en) | 2015-02-02 | 2023-12-12 | Forma Therapeutics, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3172104A (en) | 1960-06-27 | 1965-03-02 | Giannini Controls Corp | Measurement of hypersonic flight data |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5428051A (en) | 1992-10-13 | 1995-06-27 | University Of North Carolina | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
US5521189A (en) | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
US5602172A (en) | 1994-05-06 | 1997-02-11 | The University Of North Carolina At Chapel Hill | Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor |
US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
US5723495A (en) | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
JP2003523927A (ja) | 1998-08-20 | 2003-08-12 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ジカチオンジベンゾフランおよびジベンゾチオフェン化合物並びにその使用法 |
AU770656B2 (en) | 1998-09-17 | 2004-02-26 | Duke University | Antifungal activity of dicationic molecules |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
US6569853B1 (en) | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
US7250423B2 (en) | 2001-09-24 | 2007-07-31 | Chao-Jun Li | Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers |
EP1761515B1 (de) | 2003-12-20 | 2008-11-05 | MERCK PATENT GmbH | 2-(hetero-)aryl substituierte tetrahydrochinolinderivate |
DE102004031656A1 (de) * | 2004-06-30 | 2006-01-19 | Merck Patent Gmbh | Tetrahydrochinoline |
DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
-
2007
- 2007-03-20 DE DE102007013854A patent/DE102007013854A1/de not_active Withdrawn
-
2008
- 2008-02-22 MX MX2009009917A patent/MX2009009917A/es unknown
- 2008-02-22 BR BRPI0808742-3A patent/BRPI0808742A2/pt not_active IP Right Cessation
- 2008-02-22 AU AU2008228570A patent/AU2008228570A1/en not_active Abandoned
- 2008-02-22 EP EP08715973A patent/EP2121706A1/de not_active Withdrawn
- 2008-02-22 JP JP2009553939A patent/JP2010521505A/ja active Pending
- 2008-02-22 KR KR1020097021813A patent/KR20090130071A/ko not_active Application Discontinuation
- 2008-02-22 US US12/531,602 patent/US20100076012A1/en not_active Abandoned
- 2008-02-22 EA EA200901180A patent/EA200901180A1/ru unknown
- 2008-02-22 CA CA002681261A patent/CA2681261A1/en not_active Abandoned
- 2008-02-22 CN CN200880008933A patent/CN101636401A/zh active Pending
- 2008-02-22 WO PCT/EP2008/001422 patent/WO2008113456A1/de active Application Filing
- 2008-03-19 AR ARP080101127A patent/AR065786A1/es unknown
-
2009
- 2009-09-15 IL IL200966A patent/IL200966A0/en unknown
- 2009-10-19 ZA ZA200907306A patent/ZA200907306B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101636401A (zh) | 2010-01-27 |
DE102007013854A1 (de) | 2008-09-25 |
AR065786A1 (es) | 2009-07-01 |
ZA200907306B (en) | 2010-07-28 |
JP2010521505A (ja) | 2010-06-24 |
KR20090130071A (ko) | 2009-12-17 |
IL200966A0 (en) | 2010-05-17 |
US20100076012A1 (en) | 2010-03-25 |
WO2008113456A1 (de) | 2008-09-25 |
BRPI0808742A2 (pt) | 2014-08-12 |
AU2008228570A1 (en) | 2008-09-25 |
EA200901180A1 (ru) | 2010-04-30 |
CA2681261A1 (en) | 2008-09-25 |
EP2121706A1 (de) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY153727A (en) | Pyridazinone derivatives | |
IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
MX2009012708A (es) | Derivados de piridazinona. | |
MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
MX2010003368A (es) | Derivados de imidazol. | |
MX2009012709A (es) | Derivados de arileter-piridazinona. | |
MX2010003366A (es) | Derivados de piperidina y piperazina para el tratamiento de tumores. | |
NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
HUS1300076I1 (hu) | Diaril-hidantoin vegyületek | |
NZ620020A (en) | Heterocyclic compounds and uses thereof | |
GEP20125469B (en) | Inhibitors of akt activity | |
SG170809A1 (en) | Diarylthiohydantoin compounds | |
UA104731C2 (ru) | Ингибиторы р38 мар-киназ | |
TW200700064A (en) | Novel compounds | |
UA114417C2 (uk) | Інгібітори iap | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
MX2009009917A (es) | Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer. | |
MX2010007543A (es) | Inhibidores de iap. | |
MX2011007165A (es) | Derivados de piridazinona. | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
ZA200801332B (en) | Pentacyclic kinase inhibitors | |
GEP20125603B (en) | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | |
MX2009009916A (es) | Tetrahidroquinolinas sustituidas. |